The effect of sertraline on emotional processing: secondary analyses of the PANDA randomised controlled trial.


Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
10 2022
Historique:
pubmed: 13 1 2021
medline: 22 12 2022
entrez: 12 1 2021
Statut: ppublish

Résumé

According to the cognitive neuropsychological model, antidepressants reduce symptoms of depression and anxiety by increasing positive relative to negative information processing. Most studies of whether antidepressants alter emotional processing use small samples of healthy individuals, which lead to low statistical power and selection bias and are difficult to generalise to clinical practice. We tested whether the selective serotonin reuptake inhibitor (SSRI) sertraline altered recall of positive and negative information in a large randomised controlled trial (RCT) of patients with depressive symptoms recruited from primary care. The PANDA trial was a pragmatic multicentre double-blind RCT comparing sertraline with placebo. Memory for personality descriptors was tested at baseline and 2 and 6 weeks after randomisation using a computerised emotional categorisation task followed by a free recall. We measured the number of positive and negative words correctly recalled (hits). Poisson mixed models were used to analyse longitudinal associations between treatment allocation and hits. A total of 576 participants (88% of those randomised) completed the recall task at 2 and 6 weeks. We found no evidence that positive or negative hits differed according to treatment allocation at 2 or 6 weeks (adjusted positive hits ratio = 0.97, 95% CI 0.90-1.05, In the largest individual placebo-controlled trial of an antidepressant not funded by the pharmaceutical industry, we found no evidence that sertraline altered positive or negative recall early in treatment. These findings challenge some assumptions of the cognitive neuropsychological model of antidepressant action.

Sections du résumé

BACKGROUND
According to the cognitive neuropsychological model, antidepressants reduce symptoms of depression and anxiety by increasing positive relative to negative information processing. Most studies of whether antidepressants alter emotional processing use small samples of healthy individuals, which lead to low statistical power and selection bias and are difficult to generalise to clinical practice. We tested whether the selective serotonin reuptake inhibitor (SSRI) sertraline altered recall of positive and negative information in a large randomised controlled trial (RCT) of patients with depressive symptoms recruited from primary care.
METHODS
The PANDA trial was a pragmatic multicentre double-blind RCT comparing sertraline with placebo. Memory for personality descriptors was tested at baseline and 2 and 6 weeks after randomisation using a computerised emotional categorisation task followed by a free recall. We measured the number of positive and negative words correctly recalled (hits). Poisson mixed models were used to analyse longitudinal associations between treatment allocation and hits.
RESULTS
A total of 576 participants (88% of those randomised) completed the recall task at 2 and 6 weeks. We found no evidence that positive or negative hits differed according to treatment allocation at 2 or 6 weeks (adjusted positive hits ratio = 0.97, 95% CI 0.90-1.05,
CONCLUSIONS
In the largest individual placebo-controlled trial of an antidepressant not funded by the pharmaceutical industry, we found no evidence that sertraline altered positive or negative recall early in treatment. These findings challenge some assumptions of the cognitive neuropsychological model of antidepressant action.

Identifiants

pubmed: 33431087
doi: 10.1017/S0033291720004985
pii: S0033291720004985
pmc: PMC9647512
doi:

Substances chimiques

Sertraline QUC7NX6WMB
Antidepressive Agents 0
Selective Serotonin Reuptake Inhibitors 0

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2814-2821

Subventions

Organisme : Department of Health
ID : RP-PG-0610-10048
Pays : United Kingdom

Auteurs

Norin Ahmed (N)

Division of Psychiatry, University College London, Faculty of Brain Sciences, London, UK.

Jessica K Bone (JK)

Division of Psychiatry, University College London, Faculty of Brain Sciences, London, UK.

Gemma Lewis (G)

Division of Psychiatry, University College London, Faculty of Brain Sciences, London, UK.

Nick Freemantle (N)

Institute of Clinical Trials and Methodology, University College London, London, UK.

Catherine J Harmer (CJ)

University Department of Psychiatry, Warneford Hospital, Oxford, UK.
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.

Larisa Duffy (L)

Division of Psychiatry, University College London, Faculty of Brain Sciences, London, UK.

Glyn Lewis (G)

Division of Psychiatry, University College London, Faculty of Brain Sciences, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH